search
Back to results

PAAG-OA Treatment for Knee Osteoarthritis (IDA)

Primary Purpose

Osteoarthritis, Knee

Status
Active
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
PAAG-OA
Sponsored by
Contura
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged ≥ 18 years
  4. Clinical diagnosis of knee OA according to American College of Rheumatology criteria
  5. Definite radiographic OA in target knee at mild to severe stage (Kellgren-Lawrence 2-4)
  6. Stable dose of analgesics for the past four weeks
  7. Score of 2 or more (0-4 scale) on WOMAC question A1 (pain while walking on flat surface)
  8. Body Mass Index (BMI) <35
  9. For females of reproductive potential: use of adequate contraception must be used throughout the trial

Exclusion Criteria:

  1. Female participants who are pregnant, lactating or planning pregnancy during the course of the clinical investigation
  2. Previous intra-articular injection of polyacrylamide gel in the target knee
  3. Previous intra-articular injection with hyaluronic acid or derivatives in target knee in the previous 6 months
  4. Significant valgus/varus deformity of the knee, ligamentous laxity or meniscal instability
  5. Diseases in target knee other than OA
  6. Intra-articular injection of any substance other than hyaluronic acid (e.g. corticosteroids) in the target knee within the last 3 months
  7. Acute serious infection of any region that required hospital care or intravenous antibiotic treatment within the last 30 days, or oral antibiotic treatment within the last 14 days
  8. Skin disease or infections in the area of the injection site
  9. History of sepsis in any joint or any clinical concern for an infectious process in the target knee
  10. History of surgery in the target knee within the past 6 months
  11. Symptomatic osteoarthritis of the hips, spine or ankle, that interferes with the evaluation of the target knee
  12. Planned surgery on any lower extremity
  13. Clinically significant venous of lymphatic stasis present in the legs
  14. Suffering from any unstable or severe cardio-vascular disease
  15. Any other contraindication to intra-articular injection
  16. Any foreign material in the target joint
  17. Any significant medical condition (e.g. significant psychiatric or neurological disorders or active alcohol/drug abuse) that is unstable/poorly controlled or other factors that may interfere with study participation
  18. Treatment with systemic steroids with daily doses equivalent of >7,5 mg prednisolone
  19. Significant change in physiotherapy in lower extremities related to OA within the previous month
  20. Fibromyalgia
  21. Inflammatory or other disease/condition which may affect the knee joint (e.g. rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among others)
  22. Haemophilia
  23. Any other condition that in the opinion of the investigator puts a potential participant at risk or otherwise precludes participation in the investigation
  24. Known allergic reactions to antibiotics (azithromycin and moxifloxacin) or local anaesthesia
  25. Participation in any experimental device study within 6 months prior to enrolment, or participation in an experimental drug study within 1 month prior to enrolment

Sites / Locations

  • The Parker Institute
  • A2 Reumatologi og Idrætsmedicin
  • Reumatolog i Odense

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PAAG-OA

Arm Description

All subjects receive treatment with PAAG-OA

Outcomes

Primary Outcome Measures

Change in the WOMAC pain subscale
To evaluate the effectiveness of one injection of PAAG-OA on pain over 3 months in subjects with mild to severe knee OA. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme
WOMAC
To evaluate the effectiveness of one injection of PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme
PGA
To evaluate the effectiveness of one injection of PAAG-OA on knee OA Patient Global Assessment (PGA). PGA is reported on a 10 cm Visual Analogue Scale

Secondary Outcome Measures

Change in WOMAC
To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living over 6 and 12 months. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme
Change in PGA
To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related Patient Global Assessment (PGA) over 6 and 12 months. PGA is reported on a 10 cm Visual Analogue Scale

Full Information

First Posted
November 22, 2019
Last Updated
February 7, 2023
Sponsor
Contura
search

1. Study Identification

Unique Protocol Identification Number
NCT04179552
Brief Title
PAAG-OA Treatment for Knee Osteoarthritis
Acronym
IDA
Official Title
Prospective, Open-label Clinical Investigation of Intra-articular Polyacrylamide Hydrogel Injection in Subjects With Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 21, 2019 (Actual)
Primary Completion Date
February 7, 2020 (Actual)
Study Completion Date
November 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Contura

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multi-centre, prospective, open-label, uncontrolled, clinical investigation followed by an open-label extension clinical investigation to evaluate PAAG-OA in patients with knee osteoarthritis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
49 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PAAG-OA
Arm Type
Experimental
Arm Description
All subjects receive treatment with PAAG-OA
Intervention Type
Device
Intervention Name(s)
PAAG-OA
Intervention Description
Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
Primary Outcome Measure Information:
Title
Change in the WOMAC pain subscale
Description
To evaluate the effectiveness of one injection of PAAG-OA on pain over 3 months in subjects with mild to severe knee OA. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme
Time Frame
3 months
Title
WOMAC
Description
To evaluate the effectiveness of one injection of PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme
Time Frame
1 and 3 months
Title
PGA
Description
To evaluate the effectiveness of one injection of PAAG-OA on knee OA Patient Global Assessment (PGA). PGA is reported on a 10 cm Visual Analogue Scale
Time Frame
1 and 3 months
Secondary Outcome Measure Information:
Title
Change in WOMAC
Description
To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living over 6 and 12 months. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme
Time Frame
6 and 12 months
Title
Change in PGA
Description
To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related Patient Global Assessment (PGA) over 6 and 12 months. PGA is reported on a 10 cm Visual Analogue Scale
Time Frame
6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Male or female, aged ≥ 18 years Clinical diagnosis of knee OA according to American College of Rheumatology criteria Definite radiographic OA in target knee at mild to severe stage (Kellgren-Lawrence 2-4) Stable dose of analgesics for the past four weeks Score of 2 or more (0-4 scale) on WOMAC question A1 (pain while walking on flat surface) Body Mass Index (BMI) <35 For females of reproductive potential: use of adequate contraception must be used throughout the trial Exclusion Criteria: Female participants who are pregnant, lactating or planning pregnancy during the course of the clinical investigation Previous intra-articular injection of polyacrylamide gel in the target knee Previous intra-articular injection with hyaluronic acid or derivatives in target knee in the previous 6 months Significant valgus/varus deformity of the knee, ligamentous laxity or meniscal instability Diseases in target knee other than OA Intra-articular injection of any substance other than hyaluronic acid (e.g. corticosteroids) in the target knee within the last 3 months Acute serious infection of any region that required hospital care or intravenous antibiotic treatment within the last 30 days, or oral antibiotic treatment within the last 14 days Skin disease or infections in the area of the injection site History of sepsis in any joint or any clinical concern for an infectious process in the target knee History of surgery in the target knee within the past 6 months Symptomatic osteoarthritis of the hips, spine or ankle, that interferes with the evaluation of the target knee Planned surgery on any lower extremity Clinically significant venous of lymphatic stasis present in the legs Suffering from any unstable or severe cardio-vascular disease Any other contraindication to intra-articular injection Any foreign material in the target joint Any significant medical condition (e.g. significant psychiatric or neurological disorders or active alcohol/drug abuse) that is unstable/poorly controlled or other factors that may interfere with study participation Treatment with systemic steroids with daily doses equivalent of >7,5 mg prednisolone Significant change in physiotherapy in lower extremities related to OA within the previous month Fibromyalgia Inflammatory or other disease/condition which may affect the knee joint (e.g. rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among others) Haemophilia Any other condition that in the opinion of the investigator puts a potential participant at risk or otherwise precludes participation in the investigation Known allergic reactions to antibiotics (azithromycin and moxifloxacin) or local anaesthesia Participation in any experimental device study within 6 months prior to enrolment, or participation in an experimental drug study within 1 month prior to enrolment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henning Bliddal, MD
Organizational Affiliation
The Parker Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Parker Institute
City
Frederiksberg
ZIP/Postal Code
2000
Country
Denmark
Facility Name
A2 Reumatologi og Idrætsmedicin
City
Hillerød
Country
Denmark
Facility Name
Reumatolog i Odense
City
Odense
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

PAAG-OA Treatment for Knee Osteoarthritis

We'll reach out to this number within 24 hrs